

ASX ANNOUNCEMENT 6 June 2025

ENTITLEMENT OFFER DESPATCH

Cardiex Limited (ASX: CDX) (the **Company**), is pleased to announce that the Company has despatched the Entitlement Offer dated 6 June 2025 (**Entitlement Offer Booklet**) for its 1 for 4 fully underwritten non-renounceable pro rata entitlement offer of new fully paid ordinary shares in the Company (**New Shares**) at an issue price of \$0.04 per New Share (**Offer Price**) to raise up to approximately \$4.1 million (before costs) (**Entitlement Offer**).

Eligible shareholders may access a copy of the Entitlement Offer Booklet, along with their personalised application form by accessing: https://www.automicgroup.com.au/

Eligible shareholders are all shareholders with a registered address in Australia, New Zealand, Hong Kong, Singapore or United Kingdom as at the record date.

Eligible shareholders should read the Entitlement Offer Booklet carefully before making any investment decision regarding the Entitlement Offer. If you are in doubt about the Entitlement Offer, you should consult your professional adviser.

The closing date of the Entitlement Offer is 5:00pm (AEST) on Friday, 20 June 2025 (unless extended).

Notifications have also been sent to ineligible shareholders pursuant to ASX Listing Rule 7.7.1(b).

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au

Media Relations Melissa Hamilton melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").